1. Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma
- Author
-
Fanny Seraphine Krebs, Bianca Moura, Edoardo Missiaglia, Veronica Aedo-Lopez, Olivier Michielin, Petros Tsantoulis, Bettina Bisig, Mounir Trimech, Vincent Zoete, and Krisztian Homicsko
- Subjects
Inorganic Chemistry ,Male ,Humans ,Skin Neoplasms/genetics ,Melanoma/genetics ,Pyridones/therapeutic use ,Pyrimidinones/therapeutic use ,Protein Kinase Inhibitors/pharmacology ,Mitogen-Activated Protein Kinase Kinases/genetics ,Proto-Oncogene Proteins B-raf/genetics ,Mutation ,MAP Kinase Kinase 1/genetics ,MAP2K1 ,cancer ,modelling ,mutation ,triple-negative melanoma ,Organic Chemistry ,General Medicine ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,Catalysis ,Computer Science Applications - Abstract
The development of targeted therapies for non-BRAF p.Val600-mutant melanomas remains a challenge. Triple wildtype (TWT) melanomas that lack mutations in BRAF, NRAS, or NF1 form 10% of human melanomas and are heterogeneous in their genomic drivers. MAP2K1 mutations are enriched in BRAF-mutant melanoma and function as an innate or adaptive resistance mechanism to BRAF inhibition. Here we report the case of a patient with TWT melanoma with a bona fide MAP2K1 mutation without any BRAF mutations. We performed a structural analysis to validate that the MEK inhibitor trametinib could block this mutation. Although the patient initially responded to trametinib, he eventually progressed. The presence of a CDKN2A deletion prompted us to combine a CDK4/6 inhibitor, palbociclib, with trametinib but without clinical benefit. Genomic analysis at progression showed multiple novel copy number alterations. Our case illustrates the challenges of combining MEK1 and CDK4/6 inhibitors in case of resistance to MEK inhibitor monotherapy.
- Published
- 2023